Northern Cheyenne Tribe30 MW Wind Energy Development Grant

18
Antimicrobial susceptibility testing challenges Linda Joyce St Vincent’s Hospital Melbourne

Transcript of Northern Cheyenne Tribe30 MW Wind Energy Development Grant

Antimicrobial susceptibility testing challenges

Linda JoyceSt Vincent’s Hospital Melbourne

Bacteria/antimicrobials without breakpoints (B.A.W.B.S.)

• Enterobacteriacae• Pseudomonas aeruginosa, Acinetobacter spp, Burkholderia

cepacia, Stenotrophomonas maltophilia, Other Non-Enterobacteriacae

• Staphylococcus spp• Enterococcus spp• Haemophilus influenzae and parainfluenzae• Neisseria gonorrhoeae• Streptococcus pneumoniae• Streptococcus spp beta haemolytic group, viridans group• Neisseria meningitidis• Anaerobes

• Abiotrophia /Granulicatella spp• Aeromonas/Plesiomonas spp• Bacillus spp (not B.anthracis)• Campylobacter jejuni/coli• Corynebacterium spp• Erysipelothrix rhusiopathiae• HACEK group • Helicobacter pylori• Lactobacillus spp• Leuconostoc spp• Listeria monocytogenes• Moraxella catarrhalis• Pasteurella spp• Pediococcus spp• Vibrio spp including Vibrio cholera• Potential agents of bioterrorism

includes Arcanobacterium, Brevibacterium, Cellulomonas,Dermacter,Leifsonia,Microbacterium,Oerksovia,Rothia and Turicella

B.anthracis, Y.pestis, B.mallei, B.pseudomallei, F.tularensis and Brucella spp

Aggregatibacter, Actinobacillus, Cardiobacterium, Eikenella, Kingella spp

Challenges in developing breakpoints for uncommon organisms

• Relatively few strains available• Resistant strains may be rare• No clinical trials• Most clinical data from case reports• Laboratory data from centres doing surveys and

studies• CLSI M45-A2 guidelines for breakpoints cannot be

as stringent as standards for common species

Unusual urine isolates

• Actinobaculum schaalii (4)• Actinomyces neuii (3)• Actinomyces turiscensis (1)• Aerococcus urinae (5)• Aerococcus sanguiicola (8)• Other Aerococcus spp (5)• Arthrobacter spp (1)

Option 1- don’t test just add a comment

• “Aerococcus urinae is usually susceptible to a wide range of antibiotics including beta lactams”

• “Actinobaculum schaalii is usually susceptible to beta lactam antibiotics but resistant to trimethoprim and ciprofloxacin”

• “Actinomyces turicensis is usually sensitive to penicillin. Augmentin is the drug of choice”.

Option 2 Provide an MIC

• If necessary, a dilution method is usually the most appropriate testing method

• Physicians should be informed of the limitations of the results and advised to interpret with caution

Examples of Bacteria/antibiotics without breakpoints

• Moraxella nonliquefaciens• Streptococcus pneumoniae/ Ciprofloxacin• Propionibacterium spp/ Vancomycin Rifampicin• Enterobacteriacae/ Colistin• Enterobacteriacae (not E.coli) /Fosfomycin• Burkholderia cepacia/ Piperacillin Tazobactam,

Tigecycline, Moxifloxacin• Capnocytophaga spp• Aerobic Actinomycetes including Nocardia, Gordonia,

Tsukamurella and Rhodococcus• Salmonella spp/ Azithromycin

Reporting

• 1. Discuss with clinicianPK/PD breakpointsEUCAST website MIC distributionsPublished case studies

• 2. Report the MIC only

SUMMARY

If there are no breakpoints , review the literature for clinical reports of MIC and treatment. • Either report with comment only

OR• If the isolate is clinically significant and MIC specifically

requested for the management of the patient, use broth micro dilution method or E tests, following documented methods and QC

• Report MIC only • Always discuss with clinician or add a qualifying

comment

Questions

PK/PD (Non-species related) breakpointsEUCAST Clinical Breakpoint Table v. 4.0, valid from 2014-01-01

These breakpoints should not be used when there are species specific breakpoints, such as values or "-" in the tables.

Penicillins MIC breakpoint (mg/L)

PK/PD (Non-species related) breakpoints are based on the following dosages (See section 8 in Rationale Documents)

S ≤ R >

Benzylpenicillin 0.25 2 The non-species related S/I and I/R breakpoints are based on 600 mg x 4 (2.4 g/day) and 2.4 g x 6 (14.4 g/day) doses respectively.

Ampicillin 2 8 The non-species related breakpoints are based on doses of at least 0.5 g x 3-4 (1.5-2 g/day).

Ampicillin-sulbactam 2 8

Amoxicillin 2 8 The non-species related breakpoints are based on doses of at least 0.5 g x 3-4 (1.5-2 g/day).

Amoxicillin-clavulanate 2 8

Piperacillin 4 16 Breakpoints apply to piperacillin-tazobactam dosage of 4 g x 3.

Piperacillin-tazobactam 4 16 Breakpoints apply to piperacillin-tazobactam dosage of 4 g x 3.

Ticarcillin 8 16

Ticarcillin-clavulanate 8 16